193 related articles for article (PubMed ID: 9815624)
41. Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases.
Gagnon S; Têtu B; Dubé JY; Tremblay RR
Am J Pathol; 1990 May; 136(5):1147-52. PubMed ID: 2349965
[TBL] [Abstract][Full Text] [Related]
42. Aberrant p27kip1 expression in endocrine and other tumors.
Lloyd RV; Jin L; Qian X; Kulig E
Am J Pathol; 1997 Feb; 150(2):401-7. PubMed ID: 9033255
[TBL] [Abstract][Full Text] [Related]
43. Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas.
Dinjens WN; Ten Kate J; Kirch JA; Tanke HJ; Van der Linden EP; Van den Ingh HF; Van Steenbrugge GJ; Meera Khan P; Bosman FT
J Pathol; 1990 Mar; 160(3):195-201. PubMed ID: 1692338
[TBL] [Abstract][Full Text] [Related]
44. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
Kyprianou N; Tu H; Jacobs SC
Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
[TBL] [Abstract][Full Text] [Related]
45. [Determination of proliferation activity of prostate cancers by means of nuclear proliferation-associated formalin resistant Ki-S5 antigens].
Rudolph P; Lappe T; Kreipe H; Parwaresch MR; Schmidt D
Verh Dtsch Ges Pathol; 1993; 77():98-102. PubMed ID: 7511311
[TBL] [Abstract][Full Text] [Related]
46. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).
Kiyokawa H; Kineman RD; Manova-Todorova KO; Soares VC; Hoffman ES; Ono M; Khanam D; Hayday AC; Frohman LA; Koff A
Cell; 1996 May; 85(5):721-32. PubMed ID: 8646780
[TBL] [Abstract][Full Text] [Related]
47. The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27(Kip1) and cyclin E.
Goto Y; Kawauchi S; Ihara K; Ikemoto K; Ohi R; Kawai S; Sasaki K
Cancer Sci; 2003 May; 94(5):412-7. PubMed ID: 12824885
[TBL] [Abstract][Full Text] [Related]
48. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.
Thomas GV; Szigeti K; Murphy M; Draetta G; Pagano M; Loda M
Am J Pathol; 1998 Sep; 153(3):681-7. PubMed ID: 9736017
[TBL] [Abstract][Full Text] [Related]
49. gamma-Glutamyl transpeptidase in normal and neoplastic prostate glands.
Frierson HF; Theodorescu D; Mills SE; Hanigan MH
Mod Pathol; 1997 Jan; 10(1):1-6. PubMed ID: 9021720
[TBL] [Abstract][Full Text] [Related]
50. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining.
Raymond WA; Leong AS; Bolt JW; Milios J; Jose JS
J Pathol; 1988 Oct; 156(2):161-7. PubMed ID: 3058914
[TBL] [Abstract][Full Text] [Related]
51. Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia.
Pretlow TG; Whitehurst GB; Pretlow TP; Hunt RS; Jacobs JM; McKenzie DR; McDaniel HG; Hall LM; Bradley EL
Cancer Res; 1982 Nov; 42(11):4842-8. PubMed ID: 6181869
[TBL] [Abstract][Full Text] [Related]
52. Prostate cambial (stem)-zone and microcarcinoma: immunohistochemical and morphometric study approach.
Battaglia S; Nigrisoli E; Botticelli AR; Barbolini G
Appl Pathol; 1985; 3(4):255-61. PubMed ID: 2430599
[TBL] [Abstract][Full Text] [Related]
53. An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors.
Harper ME; Goddard L; Glynne-Jones E; Wilson DW; Price-Thomas M; Peeling WB; Griffiths K
Prostate; 1993; 23(1):9-23. PubMed ID: 7687782
[TBL] [Abstract][Full Text] [Related]
54. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.
Fero ML; Rivkin M; Tasch M; Porter P; Carow CE; Firpo E; Polyak K; Tsai LH; Broudy V; Perlmutter RM; Kaushansky K; Roberts JM
Cell; 1996 May; 85(5):733-44. PubMed ID: 8646781
[TBL] [Abstract][Full Text] [Related]
55. [Pathology of benign and malignant prostatic tumors].
Dhom G
Urologe A; 1992 Nov; 31(6):W47-55. PubMed ID: 1281358
[No Abstract] [Full Text] [Related]
56. Loss of nuclear p27(kip1) and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma.
Sgambato A; Camerini A; Genovese G; De Luca F; Viacava P; Migaldi M; Boninsegna A; Cecchi M; Sepich CA; Rossi G; Arena V; Cittadini A; Amoroso D
Cancer Sci; 2010 Sep; 101(9):2080-6. PubMed ID: 20626751
[TBL] [Abstract][Full Text] [Related]
57. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra.
Hahn P; Smith IC; Leboldus L; Littman C; Somorjai RL; Bezabeh T
Cancer Res; 1997 Aug; 57(16):3398-401. PubMed ID: 9270004
[TBL] [Abstract][Full Text] [Related]
58. Comparative pathology of benign prostatic hyperplasia and prostate cancer.
Maini A; Archer C; Wang CY; Haas GP
In Vivo; 1997; 11(4):293-9. PubMed ID: 9292295
[TBL] [Abstract][Full Text] [Related]
59. Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells.
Lu Y; Bedard N; Chevalier S; Wing SS
PLoS One; 2011 Jan; 6(1):e15936. PubMed ID: 21264218
[TBL] [Abstract][Full Text] [Related]
60. [Electron-microscopic studies of the normal prostate, prostatic hypertrophy and prostatic carcinoma].
Kirchheim D; Bacon RL
Urologe; 1968; 7(5):292-305. PubMed ID: 4178530
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
